BeOne Medicines has entered into a high-value agreement with Huahui Health, committing $20 million upfront to secure an exclusive option for a preclinical trispecific antibody candidate developed by the Chinese biotech firm. The asset, identified as HH160, targets PD-1, CTLA-4 and VEGF-A, positioning it within a growing class of multi-target oncology therapies. The arrangement gives BeOne the right to proceed with licensing under a broader Trispecific Antibody deal structure that could scale significantly in value.
HH160 was engineered using Huahui’s PolyBoost multispecific antibody platform. Preclinical findings, presented at the American Association for Cancer Research annual meeting last year, were described by the company as demonstrating the “potential to harness the synergistic anti-tumor mechanisms, overcome resistance to monotherapy, and simplify the dosing regimen.” If BeOne exercises its option, the company will pay an additional $100 million. Beyond that, the agreement includes up to $1.9 billion in milestone payments, alongside tiered royalties tied to future commercial performance.
- BeOne has also signaled interest in participating in Huahui’s future financing rounds, although those terms will be negotiated independently
- Huahui transitioned into a commercial-stage company this year following regulatory approval in China for Libevitug injection targeting chronic hepatitis D virus infection
- The therapy is currently being evaluated in a global phase 3 trial aimed at potential U.S. approval
- BeOne continues to expand its oncology portfolio, building on established assets such as Brukinsa and Tevimbra
“Huahui Health has established an integrated research and development engine covering the full drug development value chain, enabling the independent identification of novel targets and development of proprietary drug candidates,” Huahui’s CEO Chen Bin, Ph.D., said in the release.
BeOne, formerly known as BeiGene, has been strengthening its pipeline in advanced biologics, including trispecific formats. The company has already advanced BG-T187 into clinical testing, a candidate targeting EGFR and two distinct epitopes of c-Met. That program entered a phase 1 trial in 2024, evaluating both standalone and combination approaches in patients with advanced solid tumors. The latest Trispecific Antibody agreement further extends BeOne’s strategic focus on next-generation oncology biologics.
